COVID-19 Vaccine: Russia Signs Deal With Dr Reddy's For Trial & Distribution Of Sputnik V In India
Russia was the first country to license a novel coronavirus vaccine before large-scale Phase III trials were complete, stirring concern among scientists and doctors about the safety and efficacy of the shot.
Russia's sovereign wealth fund has agreed to supply 100 million doses of its coronavirus vaccine, Sputnik V, to Indian drug company Dr Reddy's Laboratories.
According to reports, upon regulatory approval in India, RDIF shall supply to Dr Reddy's 100 million doses of the vaccine.
Reuters
The Sputnik V vaccine, which is based on well studied human adenoviral vector platform with proven safety, is undergoing clinical trials for the coronavirus pandemic.
Deliveries could potentially begin in late 2020 subject to completion of successful trials and registration of the vaccine by regulatory authorities in India.
Also Read: Russian Health Minister Claims Mass Delivery Of Sputnik V COVID-19 Vaccine Will Begin In September
The agreement between RDIF and Dr Reddy's reflects the growing awareness of countries and organizations to have a diversified anti-COVID vaccine portfolio to protect their populations.
Reuters
Russia was the first country to license a novel coronavirus vaccine before large-scale Phase III trials were complete, stirring concern among scientists and doctors about the safety and efficacy of the shot.
Also Read: Ministry Of Health Confirms Being In Touch With Russia Over Sputnik V COVID-19 Vaccine
G V Prasad, Co-Chairman and Managing Director of Dr. Reddy¡¯s Laboratories said, ¡°We are pleased to partner with RDIF to bring the vaccine to India. The Phase-I and II clinical trials have shown promising results. We will be conducting Phase-III trials in India to ensure safety and efficacy for the Indian population and to meet the requirements of the Indian regulators. Sputnik V vaccine could provide a credible option in our fight against COVID 19 in India.¡±
AP
There was no detail about the price of the vaccine but RDIF has said previously it was not aiming at making a profit, just covering costs.
India is only the second country in the world to cross the grim milestone and said this week it is considering granting an emergency authorisation for a vaccine, particularly for the elderly and people in high-risk workplaces.
The RDIF has already reached vaccine supply deals with Kazakhstan, Brazil and Mexico. It has also signed a memorandum with the Saudi Chemical company.
All Inputs Reuters
